Metformin Hydrochloride Milpharm

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Milpharm, is a biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose levels in adults with type 2 diabetes mellitus and is used for long‑term management of hyperglycaemia as part of a comprehensive diabetes care plan.

GNH USA supplies Metformin Hydrochloride Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is an oral antidiabetic agent used primarily in the treatment of disorders characterized by elevated blood glucose.

Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. Prediabetes (impaired fasting glucose): helps delay progression to type 2 diabetes when combined with lifestyle modification.

Metformin Hydrochloride may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset occurring early in therapy. - Diarrhoea: loose stools that may improve with dose titration. - Abdominal discomfort: cramping or bloating often transient. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat, usually mild. - Vitamin B12 deficiency: gradual decrease with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate, especially in renal impairment. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: marked liver dysfunction leading to elevated enzymes and jaundice. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Hypoglycaemia (when combined with other antidiabetics): unusually low blood glucose levels.

When prescribing Metformin Hydrochloride, clinicians should observe the following precautions to minimise risk.

Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. Hepatic function monitoring: avoid use in patients with severe liver disease. Risk of lactic acidosis: discontinue if patient develops hypoxia, sepsis, or acute heart failure. Vitamin B12 levels: monitor during long‑term therapy as deficiency may occur. Pregnancy and lactation: assess benefits versus risks; use only if clearly needed. Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Metformin Hydrochloride can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Alcohol: potentiates risk of lactic acidosis and hypoglycaemia. - Cimetidine: can raise plasma metformin concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may affect renal function, requiring dose adjustment. - Beta‑blockers: can mask hypoglycaemia symptoms. - Diuretics (especially thiazides): may increase risk of renal impairment. - Warfarin: may alter INR, necessitating closer monitoring. - Sulfonylureas: additive hypoglycaemic effect, requiring dose titration.